Navigation Links
Pierre Fabre Dermatologie Starts Clinical Trials on a Beta-Blocker to Treat Severe Infantile Haemangioma
Date:5/6/2009

. The lesion is bright red and commonly referred to as a "strawberry mark".

Local complications may occur in the form of ulceration and critical localisations such as the eye area or the upper respiratory tract. These complications are the serious forms of the disease and represent 10% of total haemangioma occurrence, or 1% of births. First intention treatment is usually long-term systemic corticotherapy. The trouble with this kind of treatment is that it involves numerous and sometimes serious side-effects that are well known in infants.

About Pierre Fabre:

Pierre Fabre Laboratories, France's second biggest independent pharmaceutical laboratory, achieved a turnover of 1.75 billion euros in 2008. It employs nearly 10,000 people including 1,400 in the research sector. Its business sectors are ethical drugs, healthcare products and dermocosmetics with the brands Avene, Ducray/A Derma, Galenic/Elancyl, Klorane and Rene Furterer. Pierre Fabre Dermatologie, as part of Pierre Fabre Dermocosmetique, is specialised in prescription drugs.

In 2008, Pierre Fabre Medicament dedicated 33% of its annual turnover to R&D in five main therapeutic areas: oncology (priority sector with 50% of the overall R&D budget), Central Nervous System, cardiology, internal medicine/urology and dermatology. To find out more about Pierre Fabre Laboratories: http://www.pierre-fabre.com


'/>"/>
SOURCE Pierre Fabre SA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Bristol-Myers Squibb and Pierre Fabre Provide Update On Vinflunine Development Status
2. Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration
3. Evotec Starts Phase II in Smoking Cessation with EVT 302
4. Synosia Starts Phase II Efficacy Trial For Rufinamide
5. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Combination REOLYSIN(R)/Cyclophosphamide Trial
6. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
7. Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children
8. AMT Starts Collaboration With St. Jude Childrens Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy
9. Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics
10. Gerresheimer Starts Process to Sell off its Business Segment of Technical Plastics
11. Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Feb. 26, 2015 The healthcare landscape is rapidly ... Frost & Sullivan will host its 20 th ... , March 8 to 10, at the Hilton San Diego ... This event is a platform for global ... discuss industry disruptions and how to succeed in an uncertain ...
(Date:2/26/2015)... Schaumburg, IL (PRWEB) February 26, 2015 ... to its gauging line by expanding its Length Gauge ... and ACANTO gauges. , Specifically, HEIDENHAIN’s pencil ... an improved force specification. Two new 1Vpp, 12mm ... for lower force applications. One is a variant with ...
(Date:2/26/2015)... According to a new market report published ... Crops (Corn, Soybean, Cotton and Others), Synthetic Biology-Enabled Products ... Trends and Forecast, 2013 – 2019,”the global agricultural biotechnology ... and is expected to reach USD 28,694.1 million by ... to 2019. , Demand for food production has ...
(Date:2/26/2015)... OAKS, Calif. , Feb. 26, 2015 ... achieved Gold Partner status in Oracle PartnerNetwork. In attaining ... for its commitment to establish Oracle-related knowledge in delivering ... the challenges of joint customers. Originally developed ... researchers to rapidly zoom in and out of massive ...
Breaking Biology Technology:Embrace the Future of Medical Technologies with Frost & Sullivan 2Embrace the Future of Medical Technologies with Frost & Sullivan 3Accuracy and Versatile Gauging Go Hand in Hand at HEIDENHAIN 2Global Agricultural Biotechnology Market is Expected to Reach USD 28,694.1 Million in 2019 : Transparency Market Research 2Global Agricultural Biotechnology Market is Expected to Reach USD 28,694.1 Million in 2019 : Transparency Market Research 3Ceres Becomes Oracle PartnerNetwork Gold Level Partner 2Ceres Becomes Oracle PartnerNetwork Gold Level Partner 3Ceres Becomes Oracle PartnerNetwork Gold Level Partner 4
... April 8 ImQuest Life Sciences presented their ... their novel small molecule piperazine compound for the ... Therapeutics meeting held in Whistler, British Columbia. The ... lead microtubule inhibitor, IQP-0304. The piperazines demonstrate potent ...
... 8 Micromet, Inc. (Nasdaq: MITI ... for the treatment of cancer, inflammation and autoimmune ... the peer-reviewed Journal of Immunotherapy (1) demonstrating the ... to carcinoembryonic antigen (CEA) and to CD3 on ...
... 7 Pharmatech Oncology, Inc., a Research Management Organization ... companies at the Company Showcase during BIOZONA 2009 - ... Downtown on April 7th in Phoenix, Arizona.Matthew B. Wiener, ... during the first session of the conference. The ...
Cached Biology Technology:ImQuest Presentation at Keystone Symposium Focuses on Advancements in Their Cancer Research and Development Program 2Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth 2Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth 3Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth 4Pharmatech Oncology Selected to Present at Company Showcase at BIOZONA 2
(Date:2/5/2015)... Jan. 30, 2015  It is gratifying to see ... potential for genomic science as a means to better ... and treatment.  I was honored to participate in today,s ... medicine program. Since the 1980s my ... genomics—from the first sequenced genome of a free living ...
(Date:1/22/2015)... - Today, FindBiometrics, the leading source of biometrics industry news, interviews ... design. "When we launched FindBiometrics 12 years ago ... , founder and CEO of FindBiometrics. "Now it,s maturing very ... key players on a very broad scale.  We are known ...
(Date:1/22/2015)... Jan. 16, 2015  A man-made form of insulin delivered ... mental capabilities in adults with mild cognitive impairment and ... by researchers at Wake Forest Baptist Medical Center. ... amnesic mild cognitive impairment (MCI) or mild to moderate ...
Breaking Biology News(10 mins):J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3
... of Texas at Austin studying electric fish have gained new ... neurons. , Their finding, published in the Feb. 16 ... and neural disorders like epilepsy in humans. , Dr. Harold ... fish zap each other in dark waters, their neurons store ...
... who undergo surgery for breast cancer followed by ... only be corrected through reconstructive surgery. Researchers at ... with bioengineers at Carnegie Mellon University, have developed ... serve as an artificial tissue filler after surgery ...
... Union speech President Bush said technology is the best way ... of Energy Joint Genome Institute (DOE JGI) is directing the ... that will lead to cheaper and easier to produce biofuels. ... of molecular biology we can generate diagnostic fingerprints, Environmental Genomic ...
Cached Biology News:Mechanism for memory revealed in neurons of electric fish 2Chemotherapy gel may fight breast cancer and reduce breast deformity 2Environmental metagenomics diagnosing extreme environments, tapping opportunities for clean energy 2
Request Info...
The Proteome Profiler Human Phospho-MAPK Array Kit contains 4 membranes - each spotted in duplicate with 23 different MAPK antibodies....
... Anti-PLCδ-1, clone d1-174 GenBank Accession ... and X-press N-terminal tagged fusion protein corresponding ... Formulation: 0.1M Tris-glycine, pH 7.4, 0.15M NaCl, ... glycerol to 30% Quality Assurance: routinely evaluated ...
Rat CXCL7/Thymus Chemokine-1 DuoSet Economy Pack, 45 Plate...
Biology Products: